MarketBeat
17 Aug 2026, 05:02 UTC · 2h ago
Recursion Pharmaceuticals Highlights AI Platform, Roche Progress and Pipeline Updates
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
MarketBeat
17 Aug 2026, 05:02 UTC · 2h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
5 claims · each scored for market impact
Recursion's lead internal program, REC-4881, showed a reduction of over 40% in polyp burden after three months and the company is currently discussing pivotal-trial design with the FDA. — Positive efficacy data for a lead candidate coupled with FDA engagement for pivotal trials is the most direct driver of valuation for biotech companies.
+0.80Recursion has $556 million in cash, which the company expects will fund operations into at least early 2028 without additional financing. — A long cash runway eliminates immediate dilution risk and provides stability for executing the pipeline through 2027.
+0.60The company's Sanofi collaboration includes five programs that have reached their first discovery milestone, each with potential milestones up to $343 million. — Substantial milestone payments from a major pharma partner validate the platform and provide a path to non-dilutive revenue.
+0.50Continue reading
6 related stories
Search tags
Recursion has selected its first novel neuroscience target for molecule design under its 10-year collaboration with Roche. — Progressing from biological mapping to actual molecule design represents a tangible transition toward a potential therapeutic product.
+0.40Recursion reduced expenses by approximately 40% from its pro forma pre-merger level. — Operational efficiency and cost-cutting improve the margin profile and extend the cash runway.
+0.30Which stocks this story touches
The company reported positive internal pipeline data, successful partnership milestones with Roche and Sanofi, and a strong cash runway into 2028.
The company has five programs reaching their first discovery milestone through its collaboration with Recursion.
Positive progress noted in its neuroscience collaboration with Recursion, including the selection of a novel target.
[mutual] Recursion and Roche have a 10-year collaboration to build biological maps and develop neuroscience and gastrointestinal oncology programs.
[mutual] Recursion and Sanofi collaborate on designing candidates against targets of mutual interest.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
PRNewsWire
5h ago
